Role of YES1 amplification in EGFR mutation-positive non-small cell lung cancer: Primary resistance to afatinib in a patient.
Epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC) patients benefit from EGFR tyrosine kinase inhibitors (TKIs), while some patients demonstrate a resistance to EGFR-TKIs. In the case reported here, the NSCLC patient harboring an EGFR-sensitive mutation and YES1 amplification was treated with afatinib as first-line therapy, but was found to have progressive disease four weeks later. During subsequent chemotherapy, this patient's disease progressed rapidly. Mechanisms of primary resistance to EGFR-TKIs remain unclear. This case suggested that YES1 amplification might be associated with primary resistance to EGFR-TKIs and YES1 amplification might be a negative predictor of EGFR-TKI treatment in NSCLC patients harboring EGFR sensitive mutations.
['Tao|Junyan|J|0000-0002-0860-4672', 'Sun|Dantong|D|', 'Hou|Helei|H|']
D000077716:Afatinib D000368:Aged D002289:Carcinoma, Non-Small-Cell Lung D019008:Drug Resistance, Neoplasm D066246:ErbB Receptors D006801:Humans D008175:Lung Neoplasms D008297:Male D009154:Mutation D051575:Proto-Oncogene Proteins c-yes
YES1 EGFR primary resistance Afatinib NSCLC